Stock ABBV ABBVIE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases AbbVie Inc.

Equities

ABBV

US00287Y1091

Real-time Estimate Cboe BZX
Other stock markets
 12:06:23 2024-06-07 pm EDT 		5-day change 1st Jan Change
169.6 USD +0.64% Intraday chart for AbbVie Inc. +5.08% +9.33%
12:00pm AbbVie's tight grip on Humira market raises concerns about biosimilars RE
Jun. 06 AbbVie Says Mid-Stage Study of Mirvetuximab Soravtansine to Treat Ovarian Cancer Meets Primary Endpoint MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers
AQ
AbbVie - SkinMedica Celebrates 25 Years of Empowering Radiant Skin
AQ
AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer
PR
SkinMedica® Celebrates 25 Years of Empowering Radiant Skin
PR
AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383
PR
RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis
PR
Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50
PR
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors
AQ
AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
PR
AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
PR
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results
AQ
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation
AQ
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week
AQ
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
PR
QULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults
AQ
AbbVie to Present at the Bank of America Securities Healthcare Conference
PR
AbbVie : Reinforces Commitment to Science and Innovation with a €150 million Euro Investment in New Cutting-Edge Research and Development Facility in Germany
PU
AbbVie: Q1 Earnings Snapshot
AQ
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
PR
Allergan Aesthetics Invites Consumers to Be the Face of BOTOX Cosmetic and Their Other Biggest Brands
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABBV Stock
  4. News AbbVie Inc.
  5. Press Releases